Isolation, prevalence, and antimicrobial resistance profiles of Ureaplasma spp. and Mycoplasma hominis in cervical secretions from pregnant and postpartum women in Hangzhou, China Authors: Jiaming Ye, Xiaofang Xuan, Ke Xu, Meizhen Ye Published: 2026 ABSTRACT AbstractObjectiveTo evaluate the prevalence and antimicrobial resistance profiles of Ureaplasma spp. and Mycoplasma hominis in cervical secretions samples from pregnant and postpartum women in Hangzhou, China.MethodsWe performed a retrospective analysis of Ureaplasma spp. and Mycoplasma hominis culture positive rates and antimicrobial susceptibility patterns using 1,177 cervical secretion specimens, including 616 from pregnant women, 150 from postpartum women, and 411 from asymptomatic non-pregnant women attending routine gynecological check-ups. All secretion specimens were collected at Zhejiang Provincial People’s Hospital clinical microbiology laboratory between January 2017 and July 2023.ResultsAmong 1,177 participants, the overall genital mycoplasma (Ureaplasma spp. and Mycoplasma hominis) colonization rate was 51.60% (607/1,177), with significantly higher prevalence in pregnant women (57.10%, 352/616) compared to other groups. The highest colonization rate occurred in pregnant adolescents < 20 years (66.70%, 4/6). Ureaplasma spp. was the predominant detected species (51.50%, 317/616 in pregnant women), while M. hominis colonization was rare (≤ 0.80% overall). Co-colonization (Ureaplasma spp. + M. hominis) was detected in 4.90% (30/616) of pregnant women. The highest in vitro resistance rates among all genital mycoplasma-positive isolates (Ureaplasma spp. and Mycoplasma hominis) were observed for gatifloxacin (80.26%, 122/152), ciprofloxacin (69.17%, 184/266), and roxithromycin (37.70%, 92/244).ConclusionUreaplasma spp. was the predominant genital mycoplasma colonizing pregnant and postpartum women in Hangzhou, with the highest rate observed among those under 20 years of age. There was high in vitro resistance to commonly used antibiotics such as ciprofloxacin and roxithromycin among the isolates. These findings provide local epidemiologic and antimicrobial susceptibility data for pregnant and postpartum women and highlight the need for further multi-center studies to confirm regional resistance patterns and clarify their clinical implications, including when genital mycoplasma colonization may warrant intervention.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12884-026-09461-y.Keywords: Antibiotic susceptibility, Bacterial colonization, Ciprofloxacin resistance, Genital mycoplasmas, Macrolide resistance, Maternal health, Microbial epidemiology, Neonatal outcomes, Perinatal colonization, Sexually Transmitted Infections (STIs) Introduction The class Mollicutes comprises the smallest known free-living prokaryotic microorganisms capable of axenic cultivation. Within the order Mycoplasmatales, the genera Mycoplasma (e.g., M. hominis, family Mycoplasmataceae) and Ureaplasma (family Ureaplasmataceae) are clinically significant genital mycoplasmas that colonize the urogenital tract, though they represent distinct genera with differing biological characteristics [1]. Ureaplasma spp. and M. hominis are common in the cervical secretion cultures of women, which are transmissible through sexual contact. Under certain conditions, particularly in the context of immune dysregulation or high microbial load, these organisms have been associated with non-gonococcal urethritis, cervicitis, and have been implicated in some cases of intrauterine infections, miscarriages, and other adverse pregnancy outcomes [2,3]. However, it is crucial to distinguish between asymptomatic colonization, which is common, and active infection contributing to pathology. The postpartum period represents a critical window for microbial changes in the reproductive tract, as pregnancy and childbirth induce significant physiological alterations to the genital microbiota. Furthermore, the frequent administration of antibiotics for either prophylaxis or treatment during this period may substantially influence microbial resistance patterns. Of particular clinical relevance is the study of genital mycoplasma carriage (such as Ureaplasma spp. and M. hominis). Colonization with these organisms, particularly in the peripartum period, has been investigated as a potential risk factor for postpartum infectious complications in some studies. Current literature lacks comprehensive data on mycoplasma spp. prevalence, colonization patterns, and antibiotic susceptibility profiles specifically in postpartum women, highlighting an important knowledge gap in maternal healthcare. Antimicrobial agents are commonly employed in the clinical management of conditions associated with genital mycoplasmas; however, their therapeutic efficacy may be influenced by various factors, including regional prescribing practices, environmental conditions, and host factors. In recent years, the widespread use of antimicrobials has contributed to shifts in the colonization patterns and resistance profiles of M. hominis and Ureaplasma spp [4]. To systematically evaluate the prevalence of M. hominis and Ureaplasma spp. in cervical secretion samples from pregnant and postpartum women, as well as the resistance profiles to commonly used antimicrobials including macrolides, tetracyclines, and fluoroquinolones, this study retrospectively analyzed mycoplasma isolating culture results and drug susceptibility results from cervical secretion samples obtained from the clinical microbiology laboratory of Zhejiang Provincial People’s Hospital between January 2017 and July 2023. The findings aim to provide contemporary evidence to inform clinical diagnosis and therapeutic decision-making. Materials and methods Materials and ethics statement We conducted a retrospective analysis of 766 cervical secretion samples collected from pregnant women (n = 616) and postpartum women (n = 150), totaling 766 samples from the study group, at the clinical microbiology laboratory of Zhejiang Provincial People’s Hospital between January 2017 and July 2023. The samples represented patients across various gestational stages (6–40 weeks), postpartum periods, and follow-up after miscarriage or abortion. Participant ages ranged from 16 to 48 years (mean 30.18 ± 4.39 years). We established an asymptomatic control group comprising 411 cervical secretion samples from self-reported healthy, non-pregnant, reproductive-age women (aged 19–49 years; mean 31.03 ± 6.03 years). These women were recruited from individuals presenting for routine annual gynecological health check-ups at the same hospital during the study period. To be eligible for the asymptomatic control group, participants must have reported: (1) no current symptoms suggestive of genital tract infection (e.g., abnormal vaginal discharge, itching, odour, dysuria, or pelvic pain) within the past month; (2) no known diagnosis of sexually transmitted infections in the past three months; and (3) no use of systemic or intravaginal antibiotics within the past four weeks. The control group definition was therefore based on self-reported absence of genital symptoms and recent antibiotic use, and systematic laboratory exclusion of other genital infections (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, bacterial vaginosis) was not performed. Cervical secretion samples were collected as part of the standard check-up protocol, which includes screening for common reproductive tract pathogens even in asymptomatic individuals, to establish baseline microbiota profiles. Women were excluded if they were pregnant, within 6 weeks postpartum, or had any acute systemic illness. Age distributions showed no significant differences among the study groups (P > 0.05). Methods Specimen collection Patients were instructed to empty their bladder before the procedure. In a lithotomy position, the patient’s external genitalia were disinfected, and the cervix was exposed using a speculum. A sterile cotton swab was placed at the cervical and gently rotated clockwise for five turns. The swab was then removed and placed into a sterile tube for immediate laboratory testing. Mycoplasma isolating culture (including M. hominis and Ureaplasma spp.) and antimicrobial susceptibility testing The cervical secretion mycoplasma isolating culture (including M. hominis and Ureaplasma spp.) and drug susceptibility kit (Model: Type II [liquid-based]; Specification: 20 person portions per box) was produced by Zhuhai Dier Biological Engineering Co., Ltd. This kit is intended for the qualitative detection, culture, and antimicrobial susceptibility testing of genital mycoplasmas—specifically Ureaplasma spp. and M. hominis — in cervical secretions. The mycoplasma isolation, identification, and drug susceptibility testing were conducted by designated personnel following the manufacturer’s instructions and strict aseptic techniques. The specimen and liquid mycoplasma culture medium were brought to room temperature. A sterile pipette was used to transfer 100 µl of culture medium into the C-blank well of the test card. The swab was then immersed in the culture medium, twisted, and rotated to ensure the specimen was thoroughly mixed with the culture fluid. After mixing, 100 µl of the mixture was added to each well of the test card (except the C-well), followed by the addition of two drops of sterile mineral oil to each well. The drug susceptibility card was sealed and incubated at 37 °C for 24 h for Ureaplasma spp. and 48 h for M. hominis. The results were interpreted accordingly. Quality control was performed using Ureaplasma spp. ATCC 27,813 and M. hominis ATCC 14,027 reference strains, which were cultured in liquid mycoplasma culture medium. A 100 µl aliquot of the reference strain culture was added to the positive control well of the mycoplasma test card. The results were observed after 24 to 48 h. Positive results were noticed when the color of the broth changed from yellow to red with an estimated density of each organism ≥ 104 CFU. The test card was made of polyethylene material and composed as follows: Well A1 (the first well in row A, the upper row) served as the blank control well (C-).Well B1 (the first well in row B, the lower row) served as the growth control well (C+). Well A2 (the second well in row A) was the growth well for Ureaplasma spp. Well A3 (the third well in row A) was the semi-quantitative counting well for Ureaplasma spp. Well B2 (the second well in row B) was the growth well for M. hominis. Well B3 (the third well in row B) was the semi-quantitative counting well for M. hominis. It is important to note that while the kit design includes these semi-quantitative wells, the present study utilized the kit solely for qualitative detection (positive/negative results) and antimicrobial susceptibility testing; semi-quantitative data were not analyzed or reported. Row A contained high-concentration drug susceptibility wells, while row B contained low-concentration drug susceptibility wells, arranged in the specified order as follows. Antimicrobial susceptibility testing was performed for the following antibiotics: gatifloxacin, ciprofloxacin, roxithromycin, sparfloxacin, levofloxacin, ofloxacin, erythromycin, clarithromycin, azithromycin, minocycline, tetracycline, doxycycline, josamycin, telithromycin, clindamycin. The test card contained two wells with different concentrations for each antibiotic. Resistance was interpreted as follows: growth in both wells indicated resistance (R); growth only in the low-concentration well was considered intermediate (I); and no growth in either well indicated susceptibility (S). In this study, the resistance rates reported in the text and tables (e.g., Results Sect. 2.3 and Table 4) refer exclusively to isolates categorized as resistant (R) according to the manufacturer’s criteria. Isolates with intermediate (I) susceptibility were not included in these resistance rate calculations. It is important to note that the susceptibility breakpoints were defined by the kit manufacturer, as internationally recognized standards (such as CLSI or EUCAST) are not currently established for genital mycoplasmas. This should be considered when comparing these results with other studies. The specific breakpoint concentrations for all antibiotics are provided in Table 1. Table 4Antimicrobial resistance profiles of M. hominis and Ureaplasma spp. in pregnant and postpartum women [%(n/N)]Testing completeness varied by antibiotic based on clinical priority and kit configurationResistance rates indicate the percentage of isolates defined as Resistant (R). Isolates with intermediate susceptibility are not included in these ratesGiven the very small number of postpartum isolates for some antibiotics (particularly M. hominis), P-values and between-group comparisons should be interpreted with caution; the data are primarily descriptive‘-’ indicates either no growth in control wells or optional tests not performed P<0.05: statistically significant difference Antimicrobial resistance profiles of M. hominis and Ureaplasma spp. in pregnant and postpartum women [%(n/N)] Testing completeness varied by antibiotic based on clinical priority and kit configuration Resistance rates indicate the percentage of isolates defined as Resistant (R). Isolates with intermediate susceptibility are not included in these rates Given the very small number of postpartum isolates for some antibiotics (particularly M. hominis), P-values and between-group comparisons should be interpreted with caution; the data are primarily descriptive ‘-’ indicates either no growth in control wells or optional tests not performed P<0.05: statistically significant difference Table 1In vitro susceptibility breakpoints (mg/L) for Mycoplasma sppS Susceptible, R Resistant In vitro susceptibility breakpoints (mg/L) for Mycoplasma spp S Susceptible, R Resistant For full transparency, the distribution of isolates across all three categories (Susceptible, Intermediate, and Resistant) for each antibiotic is provided in Supplementary Table S1. Statistical analysis Data analysis was performed using SPSS 21.0 software. Quantitative data were expressed as mean ± standard deviation (x̄ ± s), and qualitative data were expressed as rates (%). Comparisons of rates across multiple groups were made using the Chi-square test or Fisher’s exact test (when expected cell counts were < 5). For multiple pairwise comparisons, Bonferroni correction was applied by adjusting the significance threshold to α/n (where n = number of comparisons), with corrected P-values < 0.0167 considered statistically significant (α = 0.05 for 3 comparisons). A P-value of less than 0.05 (or adjusted P-value < 0.0167 for pairwise comparisons) indicated a statistically significant difference. Results Age-specific distribution ofM. hominis and Ureaplasma spp. isolates in cervical secretions from pregnant and postpartum women The colonization rates of genital mycoplasmas (Ureaplasma spp. and M. hominis) differed significantly among the Pregnant Group, Postpartum Women Group, and Control Group. The overall mycoplasma positivity rate was 51.60% (607/1,177). The Pregnant Group showed the highest colonization rate (57.10%, 352/616), followed by the Control Group (46.00%, 189/411) and the Postpartum Women Group (44.00%, 66/150). Within the Pregnant Group, the positivity rates for the < 20 years, 21–35 years, and > 35 years subgroups were 66.70% (4/6), 57.90% (311/537), and 50.70% (37/73), respectively. The corresponding rates in the Postpartum Women Group were N/A (0/0), 44.70% (59/132), and 38.90% (7/18), and in the Control Group were 60.00% (3/5), 46.30% (150/324), and 43.90% (36/82). Statistical comparisons across age subgroups between groups are presented in Table 2. Owing to the limited sample size in the < 20 years subgroup (Pregnant Group, n = 6; Control Group, n = 5) and the absence of participants in the same subgroup of the Postpartum Group, these findings should be interpreted with caution and are presented for descriptive purposes only. Women over 35 years of age showed numerically lower colonization rates across all groups compared to younger age subgroups, although these inter-group differences were not statistically significant. (Table 2). Table 2Age-specific distribution of M. hominis and Ureaplasma spp. Isolates in Cervical Secretions from Pregnant and Postpartum Women [%(n/N)]Pairwise comparisons were performed using the Bonferroni correction for multiple testing (α = 0.05/3 ≈ 0.0167 per test). N/A: Not applicable due to zero participants in the postpartum group for the <20 years subgroupThe Overall P value was derived from the Chi-squared test or Fisher's exact test (if expected counts <5) for the comparison across all three groups.Significant results (P<0.05) are boldedSignificance levels *P<0.05, **P<0.01, ***P<0.001 Age-specific distribution of M. hominis and Ureaplasma spp. Isolates in Cervical Secretions from Pregnant and Postpartum Women [%(n/N)] Pairwise comparisons were performed using the Bonferroni correction for multiple testing (α = 0.05/3 ≈ 0.0167 per test). N/A: Not applicable due to zero participants in the postpartum group for the <20 years subgroup The Overall P value was derived from the Chi-squared test or Fisher's exact test (if expected counts <5) for the comparison across all three groups.Significant results (P<0.05) are bolded Significance levels *P<0.05, **P<0.01, ***P<0.001 Distribution of M. hominis and Ureaplasma spp. in Cervical Secretions from Pregnant and Postpartum Women The Pregnant Group exhibited the highest colonization rate (51.50%, 317/616) for Ureaplasma spp., which was significantly higher (P < 0.05) than both the Postpartum Group (38.70%, 58/150) and the Control Group (42.60%, 175/411). No significant difference was observed in Ureaplasma spp. colonization rates between the Postpartum Group and the Control Group(P > 0.05). The prevalence of M. hominis colonization was consistently low across all groups (≤ 0.80%), with no statistically significant differences (P > 0.05). The Pregnant Group showed a numerically higher co-colonization rate (Ureaplasma spp. + M. hominis) at 4.90% (30/616) compared to other groups, but this difference was not statistically significant (P > 0.05). Additionally, the negative culture rate (i.e., no M. hominis or Ureaplasma spp. detected) was lowest in the Pregnant Group (42.90%, 264/616), significantly lower than both the Postpartum Group (56.00%, 84/150; P < 0.01) and the Control Group (54.00%, 222/411; P < 0.01) (Table 3). Table 3Distribution of M. hominis and Ureaplasma spp. in Cervical Secretions from Pregnant and Postpartum Women [%(n/N)]1. Fisher's exact test was used for overall comparisons when expected cell counts were <52. Bonferroni correction applied for pairwise comparisons (adjusted α ≈ 0.0167)3. Significance levels: *P <0.05, **P<0.01, ***P<0.001 Distribution of M. hominis and Ureaplasma spp. in Cervical Secretions from Pregnant and Postpartum Women [%(n/N)] 1. Fisher's exact test was used for overall comparisons when expected cell counts were <5 2. Bonferroni correction applied for pairwise comparisons (adjusted α ≈ 0.0167) 3. Significance levels: *P <0.05, **P<0.01, ***P<0.001 Antimicrobial resistance profiles of M. hominis and Ureaplasma spp. in pregnant and postpartum women The three antimicrobials with the highest resistance rates among all positive isolates were gatifloxacin (80.26%), ciprofloxacin (69.17%), and roxithromycin (37.70%), whereas the lowest resistance rates were observed for josamycin (2.63%), telithromycin (2.31%), and clindamycin (0.47%).The highest resistance rates for Ureaplasma spp. and co-colonization cases in pregnant and postpartum women were observed with gatifloxacin (70.00%, 100.00%;80.33%, 100.00%). In our study, antimicrobial resistance patterns were observed in pregnant women colonized with M. hominis, with common antimicrobials showing limited efficacy. Among postpartum women with M. hominis colonization, only five isolates were available for susceptibility testing; of these, four(80.0%) were resistant to ciprofloxacin. Given the extremely small number of postpartum isolates, these data are presented descriptively and do not allow reliable inferences about group-level resistance patterns. In Ureaplasma spp. colonization, resistance to fluoroquinolones such as ciprofloxacin was high across groups. Although a higher proportion of ciprofloxacin-resistant isolates was observed among postpartum women than among pregnant women, the relatively small number of postpartum isolates limits the reliability and generalizability of this comparison, and these findings are best interpreted descriptively (Table 4). A numerical trend toward higher roxithromycin resistance was observed in pregnant women (52.63%) compared to Postpartum women (32.95%), although this difference did not reach statistical significance (P > 0.05; Table 4). The resistance rates presented in this section and in Table 4 reflect the proportion of isolates categorized as resistant (R). The complete distribution of isolates across susceptible, intermediate, and resistant categories for all antibiotics is provided in Supplementary Table S1. Discussion Genital mycoplasmas (Ureaplasma spp. and M. hominis ) represent important urogenital colonizing microorganisms that can cause female genital tract infections, with reported detection rates showing an increasing incidence trend in recent years [5–6]. The escalating antimicrobial resistance observed in these mycoplasmas, partly attributed to inappropriate antimicrobial use, presents growing challenges for clinical management in pregnant and postpartum populations. This study found that among the mycoplasma culture results from cervical secretion samples of pregnant and postpartum women, Ureaplasma spp. was the most frequently detected species, indicating its role as a predominant component of the genital tract microbiota in this population. This pattern of distribution, where Ureaplasma spp. colonization predominates, is consistent with the findings of Liang Xianzhi [7] and Xue Guoshuang [8]. Our study also found that the detection rate of Ureaplasma spp. alone was significantly higher in pregnant women than in our control group. The overall mycoplasma positivity rate in our study population was 51.60%(607/1,177), which is numerically higher than rates reported in South Korea (39.40%) [9] and Fushun, China (28.17%) [10], and numerically lower than the rate reported in Beijing (54.69%) [11], reflecting geographic variability in colonization prevalence. These findings indicate a higher prevalence of genital mycoplasma colonization in our cohort of pregnant and postpartum women compared to non-pregnant controls. The physiological state of pregnancy and postpartum may influence colonization dynamics due to hormonal changes, increased glycogen content in cells, and immunological adaptations, which can alter the reproductive tract microbiota. The clinical significance of this increased colonization rate, and whether it translates to a higher risk of adverse outcomes, requires further investigation and should be evaluated in the context of individual patient symptoms and risk factors. The particularly high colonization rate in our pregnant cohort (57.10%) suggests regional characteristics warranting further study. This study found that in the pregnant group, the colonization rates for those under 20 years old, between 21 and 35 years old, and over 35 years old were all numerically higher than those in the control group. A numerically high mycoplasma positivity rate was observed in the subgroup of women under 20 years of age; however, this finding should be interpreted with caution due to the small sample size (n = 6). Song [12], Wang [13] and others found that the colonization rate in women under 20 years old was the highest, reaching 58%-60%, which is directionally consistent with the trend observed in our data [14]. This might indicate a potentially higher susceptibility to genital mycoplasma colonization in younger women, although the limited subgroup size in our study precludes definitive statistical conclusions. The elevated genital mycoplasma colonization rate in pregnant adolescents (< 20 years: 66.70%) (based on a small sample, n = 6) may reflect synergistic biological and behavioral risks. Younger women often exhibit thinner cervical epithelium, facilitating microbial colonization, while socioeconomic barriers can delay diagnosis. Thus, young age (under 20 years old) might be a potential risk factor for Mycoplasma colonization, especially in pregnant individuals, but further investigation with larger samples is required to confirm this association. This pattern is considered to be related to the hormonal levels, as well as more complex lifestyle and behavioral patterns after conception across age groups [15]. It is important to emphasize that the sample size of pregnant women under 20 years old in our study was very small (n = 6), and therefore these results should be interpreted with caution and regarded as descriptive in nature. While our findings align with prior reports of higher mycoplasma positivity rates in younger populations [12–14], caution is warranted in interpreting these results due to potential sampling variability. Future studies with larger, age-stratified cohorts are needed to validate these observations. This study revealed that in the postpartum group, the colonization rates for both the 21–35 years old and over 35 years old subgroups were significantly lower than those in the control group. Notably, our postpartum cohort included no subjects under 20 years of age. Marti DT suggested that the reduced detection rate of reproductive tract microorganisms in postpartum women may be associated with antibiotic use during pregnancy [16]. Several factors may contribute to this phenomenon. First, the administration of antibiotics for infection prophylaxis following birth canal trauma or alterations in the immune environment during delivery may inadvertently suppress mycoplasma colonization [17]. Additionally, the timing of sample collection in postpartum women (immediately after delivery) is noteworthy, as the mechanical clearance effect during childbirth (e.g., through amniotic fluid expulsion) could transiently reduce the microbial load, including Mycoplasma species. In contrast, control group samples were obtained during routine gynecological examinations, which likely reflect more accurate baseline genitalium mycoplasma colonization levels. Ureaplasma spp.-induced peripartum infections have become a new challenge for modern obstetrics [18]. Oh KY [19] and colleagues found that 60.20% (106/176) of pregnant Korean women exhibited positive results in Ureaplasma spp. cultures, and the positive rate for M. hominis was 1.1%, both higher than the rates observed in the pregnant women(51.50%;0.80%) and the postpartum women (38.70%;0.70%) in this study. Scoullar MJL [20] found a 12.50% positive rate for M. genitalium in pregnant women in Papua New Guinea, indicating that the spectrum of mycoplasma species and corresponding colonization rates of clinical concern vary across geographical regions. It is necessary to collect systematic data on the colonization rates and clinical implications of genital mycoplasmas in pregnant women [21], and to establish a global surveillance system for monitoring their prevalence and resistance patterns [22]. Women should receive appropriate health education regarding genital tract infections and antimicrobial resistance [23]. Our study observed prevalent fluoroquinolone resistance (e.g., to ciprofloxacin and ofloxacin) in cervical Ureaplasma spp. and M. hominis isolates from pregnant and postpartum women, a pattern that is consistent with previous reports linking empirical fluoroquinolone use to rising resistance, although causal relationships cannot be inferred from our retrospective design [24–26]. Nevertheless, these strains retained susceptibility to several alternatives agents. Tetracyclines such as doxycycline demonstrated low resistance rates (< 10.00%) in our cohort, which aligns with findings from regional studies [8, 27, 28], though reported resistance elsewhere ranging between 43% and 73% underscores the importance of geographic variability [29, 30]. Macrolides including clarithromycin showed high efficacy against Ureaplasma spp., with resistance rates of 5.00–8.40% in mono-colonization versus 18.50–42.90% in cases co-colonized with M. hominis. The high placental transfer rate of clarithromycin, combined with lower resistance (0.90–25.00%) among pregnant patients compared to other macrolides, supports its use as a preferred option for Ureaplasma spp. mono-colonization during pregnancy [31, 32]. Although Lendamba et al. [33] reported widespread macrolide resistance in genital mycoplasmas, clarithromycin remained effective against single-strain Ureaplasma spp. colonization. Clindamycin, which is safe in pregnancy and active against M. hominis (including fluoroquinolone-resistant strains), exhibited minimal resistance. Pristinamycin (resistance < 10.00%) represents another option for multidrug-resistant cases, though its use may be limited by regional availability. For pregnant women, current clinical practice generally prefers erythromycin or clindamycin (for M. hominis), and clarithromycin (for Ureaplasma spp.), given their safety profiles in pregnancy and the relatively favorable resistance rates observed in our cohort and prior studies. Teratogenic agents such as tetracyclines and fluoroquinolones should be avoided [27, 34]. Antibiotic resistance is a primary cause of treatment failure in conditions associated with genital mycoplasmas, and the increasing prevalence of resistant strains has prompted ongoing surveillance studies [35]. The development of novel antimicrobial agents capable of addressing the current resistance crisis represents an urgent need [36]. Zoliflodacin is the first synthetically produced antibiotic of the fluoroquinolone class [37], which exerts its activity against M. genitalium by binding to distinct sites on bacterial type II topoisomerase [38]. Additionally, metalloantibiotics—metal complexes synthesized by bacteria that exhibit antibacterial activity—represent another emerging area worthy of attention [39]. Regional susceptibility testing remains critical prior to treatment, especially during pregnancy. In refractory cases, emerging agents such as zoliflodacin or metalloantibiotics may hold promise, though clinical data are still limited. The high detection rate of genital mycoplasmas in our study population necessitates careful clinical interpretation. Notably, Ureaplasma spp. was detected in 42.60% of asymptomatic control group women in our study, consistent with previous reports that Ureaplasma species (including Ureaplasma parvum) are frequently isolated from normal cervical secretions as part of the commensal flora [12, 36]. This finding highlights the critical distinction between colonization and clinically relevant infection. A positive culture alone does not necessarily indicate pathology or require antibiotic intervention. Treatment decisions should therefore be guided by clinical context, reserving antimicrobial therapy for symptomatic women or those with high-risk obstetric conditions (e.g., history of preterm birth, pregnancy loss, or other complications) where genital mycoplasmas have been implicated in adverse outcomes. Asymptomatic colonization in low-risk individuals may be managed through watchful observation rather than empirical treatment. Notably, we did not differentiate Ureaplasma parvum from Ureaplasma urealyticum in this study. This represents a significant limitation for clinical interpretation. U. parvum is frequently detected as part of the normal vaginal flora and asymptomatic colonization is common, whereas U. urealyticum has been more often reported in association with adverse reproductive outcomes. Moreover, previous studies have suggested species-specific differences in antimicrobial susceptibility, with U. parvum tending to show lower macrolide resistance and U. urealyticum sometimes exhibiting relatively higher fluoroquinolone resistance. Consequently, our composite susceptibility estimates for “Ureaplasma spp.” (for example, the 69.17% ciprofloxacin resistance observed among Ureaplasma isolates in this cohort) should be interpreted as genus-level values rather than as species-specific rates. Future work incorporating molecular speciation will be needed to refine species-specific risk and resistance estimates. This study has several limitations that should be acknowledged. First, as a single-center investigation conducted at Zhejiang Provincial People’s Hospital, our findings may lack generalizability. A multicenter study with broader geographic representation would strengthen the validity of the results. Second, the retrospective design inherently limited our ability to include all eligible pregnant and postpartum women, resulting in a relatively small sample size for mycoplasma culture analysis and particularly for drug susceptibility testing. The extremely low prevalence of M. hominis mono-colonization (n = 9, 0.8% of total cohort) significantly constrained our ability to perform meaningful subgroup analyses. For example, the observed ciprofloxacin resistance rate of 80% among postpartum women with M. hominis was based on merely 5 cases, and such findings must be interpreted with considerable caution due to the substantial risk of sampling bias. Methodologically, while our approach successfully differentiated Ureaplasma spp. from M. hominis, we were unable to speciate between U. parvum and U. urealyticum. As a result, all reported resistance rates for Ureaplasma represent aggregated genus-level values, and species-specific differences in colonization patterns and susceptibility may not be captured by our data. We attempted to mitigate this limitation through parallel culturing in selective media with morphological confirmation. Furthermore, although we applied specific criteria to define our asymptomatic control group (asymptomatic, no recent antibiotics or STI diagnosis), the selection was based on self-reported health status during routine check-ups. This approach may not have captured all subclinical conditions or subtle variations in genital microbiota that could influence colonization rates. Therefore, the comparability between groups, while strengthened by explicit criteria, should still be interpreted within the context of this potential residual confounding. Finally, while we report mycoplasma colonization rates, our study design did not permit evaluation of the potential causal relationships between these colonizations and adverse pregnancy outcomes - an important area for future investigation. In summary, Ureaplasma spp. was the most prevalent genital mycoplasma in pregnant and postpartum women in Hangzhou, with the highest colonization rate among women under 20 years of age. Given the high in vitro resistance rates to commonly used antibiotics in our setting(e.g., ciprofloxacin: 69.17%; roxithromycin: 37.70%), antimicrobial susceptibility testing, where available, is important to inform therapy when treatment is clinically indicated. These local resistance data may help contextualize empirical choices in Hangzhou and underscore the need for multi-center studies that incorporate species-level identification, longitudinal follow-up, and clinical outcomes to better define when genital mycoplasma colonization warrants intervention. Supplementary Information Supplementary Material 1. Acknowledgements We are grateful to all patients, doctors, and study nurses associated with the participating study. Authors’ contributions Data curation, Jiaming Ye and Meizhen Ye; Formal analysis, Xiaofang Xuan, Meizhen Ye; Investigation, Jiaming Ye; Methodology, Xiaofang Xuan, Ke Xu; Project administration, Meizhen Ye; Supervision, Ke Xu; Writing – original draft, Ke Xu. All authors have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Funding This work was supported by the Fund for Zhejiang Medical and Health Science and Technology Program(2025KY606, 2024KY712, 2024KY755).The funding supporters did not participate in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Data availability The majority of datasets used and/or analyzed during the current study are available from the indicated published resources. The remaining data, including model code, are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Zhejiang Provincial People’s Hospital (Approval No.: 2023-QT-359). The requirement for informed consent was waived by the ethics committee because this retrospective study used fully anonymized data with no identifiable personal information, in compliance with: Article 39 of China’s Ethical Review Measures for Biomedical Research Involving Humans (2016), and Article 13 of the Personal Information Protection Law (China, 2021). All procedures adhered to institutional guidelines, national regulations, and the principles of the Declaration of Helsinki. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jiaming Ye and Xiaofang Xuan contributed equally to this work. Contributor Information Ke Xu, Email: 398894073@qq.com. Meizhen Ye, Email: yeziyezi0123@126.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The majority of datasets used and/or analyzed during the current study are available from the indicated published resources. The remaining data, including model code, are available from the corresponding author on reasonable request.